Survodutide is an experimental dual GLP-1/glucagon receptor agonist developed by Zealand Pharma and Boehringer Ingelberg currently in phase 3 trials. Unlike tirzepatide (GLP-1/GIP), survodutide combines GLP-1 appetite suppression with glucagon's effects on energy expenditure and hepatic glucose metabolism. Phase 2 data showed up to 18.7% weight loss at the highest dose. The glucagon component may provide additional benefits for fatty liver disease and metabolic rate. If approved, it would represent another dual-mechanism option alongside tirzepatide, with potentially different side effect profiles and efficacy patterns. Results from the SYNCHRONIZE phase 3 program are expected in 2025-2026.
Find a qualified GLP-1 provider
Compare pricing, clinical oversight, and patient reviews across verified telehealth programs and local clinics.
Compare Providers →Still have questions?
A qualified GLP-1 provider can give you personalized answers based on your medical history and goals.
Get answers to your GLP-1 questions
Weekly updates with the latest research, pricing changes, and expert guidance — delivered to your inbox.
No spam. Unsubscribe anytime.
Ready to start your GLP-1 journey?
Compare verified providers on pricing, medication sourcing, clinical oversight, and patient reviews — all in one place.